An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
PrimeC slowed lung function decline and complication-free survival when treatment started early, per data from a Phase 2b ALS clinical trial.| ALS News Today
Starting treatment with PrimeC six months sooner was associated with slower disease progression and a survival benefit for ALS patients.| ALS News Today
PrimeC led to improvements in iron accumulation in people with amyotrophic lateral sclerosis (ALS) in a clinical trial, new data showed.| ALS News Today